Semaglutide demonstrates favorable safety profile with 43% reduction in serious adverse events in adults with established ASCVD: a systematic review and meta-analysis of randomized controlled trials
29 August 2026 (10:15 - 11:00)
Organised by: 
About the speaker
HonorHealth Scottsdale Shea Medical Centre, Scottsdale (United States of America)
6 More presentations in this session
Doctor C. Gurevitz (Petah Tikva, IL)
Professor G. Fazio (Palermo, IT)
Doctor K. Katogiannis (Athens, GR)
Access the full session
The Event
ESC Congress 2026
29 August 2026
10:15 CET
You may be interested in
Congress Presentation
Congress Session
